Figure 6.
Figure 6. Vascular potential of FLK-1+ cells from Scl+/+ and Scl-/- EBs. (A) FLK-1+ cells from day 3.0 Scl+/+ or day 3.5 Scl-/- EBs were cultured on gelatin-coated wells in the presence of VEGF and bFGF for 3 days. Following culture the cells were harvested and stained for CD31, FLK-1, VECAD, and SMA. Numbers indicate the percentage of the respective populations. (B) Immunohistochemistry of day 3 Scl+/+ FLK-1+ cells (Scl+/+) and day 3.5 Scl-/- FLK-1+ cells (Scl-/-) cultured on fibronectin-coated glass coverslips for 3 days. CD31+ cells are shown in red, whereas the SMA+ cells are indicated in green. Original magnification, × 200. Objective × 20, numerical aperture 0.70. OpenLab software was used to analyze the images. (C) FLK-1+ cells from day 3 Scl+/+ or day 3.5 Scl-/- EBs were allowed to aggregate by culturing at high density in low-adherence plates. The aggregates were cultured for 3 days in VEGF and bFGF and then processed for CD31, FLK-1, VECAD, and SMA as described in panel A. (D) RT-PCR analyses of day 3.0 Scl+/+ FLK-1+ sorted cells (+/+, S), Scl+/+ adherent cells (+/+, Ad), Scl+/+ aggregated cells (+/+, Agg), Scl-/- day 3.5 FLK-1+ sorted cells (-/-, S), Scl-/- adherent cells (-/-, Ad) and Scl-/- aggregated cells (-/-, Agg). Hybridization was carried out with probes designed against the 3′ UTR of the indicated genes. (E) RT-PCR analysis of day 3.0 Scl+/+ FLK-1+ sorted cells (+/+, S), Scl+/+ adherent cells (+/+, Ad), and Scl+/+ aggregated cells (+/+, Agg) for the expression of the macrophage-specific genes c-fms, f4/80, CD11b, for the erythroid-specific gene, β-major, and for the endothelial-specific gene, VWF. β-Actin was used to normalize the content of cDNA in these populations.

Vascular potential of FLK-1+ cells from Scl+/+ and Scl-/- EBs. (A) FLK-1+ cells from day 3.0 Scl+/+ or day 3.5 Scl-/- EBs were cultured on gelatin-coated wells in the presence of VEGF and bFGF for 3 days. Following culture the cells were harvested and stained for CD31, FLK-1, VECAD, and SMA. Numbers indicate the percentage of the respective populations. (B) Immunohistochemistry of day 3 Scl+/+ FLK-1+ cells (Scl+/+) and day 3.5 Scl-/- FLK-1+ cells (Scl-/-) cultured on fibronectin-coated glass coverslips for 3 days. CD31+ cells are shown in red, whereas the SMA+ cells are indicated in green. Original magnification, × 200. Objective × 20, numerical aperture 0.70. OpenLab software was used to analyze the images. (C) FLK-1+ cells from day 3 Scl+/+ or day 3.5 Scl-/- EBs were allowed to aggregate by culturing at high density in low-adherence plates. The aggregates were cultured for 3 days in VEGF and bFGF and then processed for CD31, FLK-1, VECAD, and SMA as described in panel A. (D) RT-PCR analyses of day 3.0 Scl+/+ FLK-1+ sorted cells (+/+, S), Scl+/+ adherent cells (+/+, Ad), Scl+/+ aggregated cells (+/+, Agg), Scl-/- day 3.5 FLK-1+ sorted cells (-/-, S), Scl-/- adherent cells (-/-, Ad) and Scl-/- aggregated cells (-/-, Agg). Hybridization was carried out with probes designed against the 3′ UTR of the indicated genes. (E) RT-PCR analysis of day 3.0 Scl+/+ FLK-1+ sorted cells (+/+, S), Scl+/+ adherent cells (+/+, Ad), and Scl+/+ aggregated cells (+/+, Agg) for the expression of the macrophage-specific genes c-fms, f4/80, CD11b, for the erythroid-specific gene, β-major, and for the endothelial-specific gene, VWF. β-Actin was used to normalize the content of cDNA in these populations.

Close Modal

or Create an Account

Close Modal
Close Modal